Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer

  Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]

The Role of Genomics in Patients With Advanced Prostate Cancer

  H&O  What are the main technologic advances that have spurred on the current interest in genomics? MH  The current interest in genomics was a downstream […]

Optimal Use of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer

  H&O What is the treatment protocol for patients with mCRPC? DG  An exciting aspect of the field today is that there are many options for the […]

Prognostic and Predictive Biomarkers in Metastatic Castration-Resistant Prostate Cancer

  H&O  What are biomarkers in the context of metastatic castration-resistant prostate cancer (mCRPC)? AJA  Biomarkers are any manifestation of a biological process, particularly in patients, […]

Circulating Tumor Cells in Prostate Cancer: Beyond Enumeration

  Abstract: Circulating tumor cells (CTCs) are a population of rare cancer cells that have detached from the primary tumor and/or metastatic lesions and entered the […]

Prognostic Biomarkers in Early-Stage Prostate Cancer

  H&O  What is the traditional way for oncologists to determine prognosis in early-stage prostate cancer? EK  The tools traditionally used to determine prognosis are the […]

Update on the Biology and Management of Neuroendocrine Prostate Cancer

H&O What is the definition of neuroendocrine prostate cancer (NEPC)? HB NEPC is an aggressive variant of prostate cancer that typically is diagnosed in the later stages […]

Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

H&O How common is resistance to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC)? ESA Approximately 15% to 25% of patients with CRPC do not respond to […]